Although it has been suggested that the CIMP-specific DNA methylation targets may be non-overlapping and manifested by several molecular pathways across different tumor types [22], testing the CIMP status of glioma tumors only provides a subjective assessment of IDH mutation status. Here, IDH2 is linked to central nervous system cancer.